Comparison of Functional Outcomes Between Robotic and Laparoscopic Surgery in Rectal Cancer Patients: Systematic Review & Meta-Analysis doi.org/10.1080/08941939.202…

Axillary treatment options in clinically node-positive breast cancer whose nodes become pathologically node-negative after neoadjuvant chemotherapy: a pairwise and network meta-analysis doi.org/10.1080/07853890.202…

INDIGO trial Gr2 IDH mutant Gliomas woth Residual / Recurrent tumour Vorasedinib Vs Placebo NEJM 2023 Updated Analysis from ASCO 2026 added

Long-Term Analysis of NRG Oncology RTOG 0539: A Phase II Trial of Observation for Low-Risk Meningioma and Radiotherapy for Intermediate- and High-Risk Meningioma DOI doi.org/10.1200/JCO-25-01441

Mediastinal Over-staging with PET-CT in Tuberculosis-Endemic Locally Advanced NSCLC: SUV Threshold Recalibration Improves PET/EBUS Concordance

Heterotropic Ossificans An overview for Radiation oncologist

Lattice Radiotherapy An overview

🧠 PD-1 vs PD-L1 — Never Confuse Them Again! 🎯 Easy Memory Trick: 👮 PD-1 = Police (T Cell) 🦠 PD-L1 = People (Tumor Cell) Think of the T cell as a police officer fighting cancer. ✅ PD-1 is the inhibitory receptor on activated T lymphocytes. ✅ PD-L1 is the ligand expressed on tumor cells, APCs, and stromal cells. ✅ When PD-L1 binds PD-1, the immune response is switched off, allowing tumor immune escape. 💡 High-Yield Exam Pearl: “Receptors stay on T cells, ligands stay on tumor/APC cells.” Remember: 🔹 PD-1 = Player 1 = T Cell 🔹 PD-L1 = Lying Tumor = Tumor Cell A simple concept that forms the basis of modern cancer immunotherapy! #MedicalOncology #Immunotherapy #PD1 #PDL1 #CheckpointInhibitors #CancerImmunotherapy #OncologyEducation #MedEd #FOAMed #NEETSS #DrNBOncology #DMOncology #ASCO #ESMO #CancerConceptsExplained #OncologyResidents #MedicalEducation #HematologyOncology #CancerResearch #LearningMadeEasy

EMERALD 3 Trial ASCO 2026 Unresectable HCC eligible for TACE

REaCT-ZOL Trial Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer NEJM 2026

TALAPRO-3 Adding Talazoparib to Enzalutamide in mCSPC With HRR Gene Alterations ASCO 2026 meeting

Triple Oral Metronomic Chemo Ultra-Low–Dose IO Significantly Improves Survival Outcomes in Recurrent or Metastatic HNSCC ASCO 2026 TMH trial

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1

Should asymptomatic brain metastases in oncogene-driven NSCLC receive upfront cranial RT or can radiation safely be deferred Ph III trial TMH trial

“📊 Adjuvant Treatment After Upfront Surgery in Upper Tract Urothelial Carcinoma (UTUC) After radical nephroureterectomy (RNU) for high-risk localized UTUC, adjuvant platinum-based chemotherapy is now standard of care (pT2–T4 or pN disease) — driven by the landmark POUT trial. ✅ Preferred: Gemcitabine Cisplatin ✅ If cisplatin-ineligible (very common post-RNU due to sharp GFR drop): Gemcitabine Carboplatin Key nuance unique to UTUC (unlike bladder cancer): In bladder urothelial carcinoma, cisplatin remains strongly preferred and carboplatin is generally suboptimal. But in UTUC, nephroureterectomy often renders patients cisplatin-ineligible — making Gem Carbo a practical and evidence-based alternative here. Always reassess renal function post-RNU. Consider neoadjuvant chemo preoperatively whenever feasible (kidneys still intact!). Full practical guide clinical pearls in the infographic 👇 #UTUC #UrothelialCarcinoma #BladderCancer #MedOnc #UroOnc #CancerCare @DrRupamOncology”

Short Term Fasting around Chemotherapy for High Grade Serous Ovarian Carcinoma 36 h before chemo 24 h after chemo Allowed=water & herbal tea, < 2 liters of vegetable juice, & small amounts of light vegetable broth. Allowed <350 calories/day Insulin response =Key

Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST tria) ASCO 2026

Breast cancer surgery is entering its de-escalation era. AGO 2026 just pushed the field another step forward: 🔹 Omit SLNB in selected low-risk cN0 patients 🔹 Prefer TAD over ALND after NACT 🔹 Reserve full axillary dissection mainly for residual macrometastatic disease The axilla is no longer “one-size-fits-all.” Biggest shift? Patients converting from cN → ycN0 after neoadjuvant therapy may avoid the morbidity of ALND without compromising regional control. Less lymphedema. Less neuropathy. Less long-term toxicity. More precision. More personalization. The modern breast surgeon is no longer just removing disease. They are actively preserving quality of life. 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BreastCancer #BreastSurgery @OncoAlert @myesmo @esmo_open @ASCO

Adjuvant RT Breast Cancer When Concurrent TdXd is being considered Understand Risks Involved... When not to be Hero